Almitas Capital LLC Invests $1.13 Million in Alto Neuroscience, Inc. (NYSE:ANRO)

Almitas Capital LLC bought a new stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 266,912 shares of the company's stock, valued at approximately $1,129,000. Almitas Capital LLC owned 0.99% of Alto Neuroscience as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wells Fargo & Company MN grew its position in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after acquiring an additional 3,139 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock valued at $108,000 after buying an additional 5,008 shares during the period. Bank of New York Mellon Corp lifted its stake in Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock worth $221,000 after acquiring an additional 6,812 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after acquiring an additional 7,783 shares during the last quarter. Finally, Barclays PLC raised its holdings in Alto Neuroscience by 34.5% during the fourth quarter. Barclays PLC now owns 39,807 shares of the company's stock worth $168,000 after purchasing an additional 10,208 shares in the last quarter.

Alto Neuroscience Stock Up 1.1 %

ANRO stock traded up $0.03 during trading on Wednesday, reaching $2.22. The stock had a trading volume of 294,668 shares, compared to its average volume of 379,243. The firm has a fifty day moving average price of $2.54 and a 200 day moving average price of $3.67. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $59.96 million, a P/E ratio of -0.87 and a beta of 1.87. Alto Neuroscience, Inc. has a 1-year low of $1.60 and a 1-year high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.09. On average, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ANRO. HC Wainwright initiated coverage on Alto Neuroscience in a research report on Monday, April 7th. They issued a "buy" rating and a $10.00 target price for the company. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.